ADMA ADMA Biologics, Inc.
XNAS
12.96
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ADMA
$12.96
—
What changed
Recent filings, trades and movesKey stats
$12.96
- 52-Week Range
- $7.21 – $20.46
- YTD
- -27.54%
- IV Rank (30D)
- 4.41
- Straddle Price
- $1.50
- P/C Vol Ratio
- 0.31
- Market Cap
- $2.8B
- Open
- $12.90
- Day Range
- $12.48 – $13.06
- Volume
- 1,912,053
- Prev Close
- $12.73
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.76 |
| Cost of Equity (CAPM) | 8.68% (VRP-adj) |
| WACC | 8.55% |
| Volatility Risk Premium | -6.3pp (IV − HV30) |
| Effective Tax Rate | 22.0% |
| Rev. Growth (YoY, DCF input) | -7.3% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 41.4% |
| Book / Price | 13.9% |
| Gross Margin (TTM) | 64.7% |
| FCF Margin (TTM) | 22.7% |
| Debt / Equity | 0.47 |
| Quality Score | 5/6 — high quality (12y DCF) |
| Market-Implied Growth | +8.9% (reverse-DCF on current price) |
| SMA 50 | $10.21 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $11.12 |
| Bollinger Width / SMA20 | 26.2% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $3B |
Peers used for multiples: ALKS, AMGN, EXEL, GILD, GMAB, NBIX, REGN, TGTX
60-Day Conviction
13%
20-Day Fair Value
≈ by Dec 8, 2026
$12.91
α -0.4%
rank 28%
conviction
33%
40-Day Fair Value
≈ by Jan 6, 2027
$13.23
α +2.0%
rank 29%
conviction
64%
60-Day Fair Value
≈ by Feb 4, 2027
$13.03
α +0.5%
rank 33%
conviction
13%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $4.28 | 32% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $14.07 | 14% | median 20.1× · 5 peers |
| Peer EV/EBITDA | $16.51 | 14% | median 17.2× · 7 peers |
| Peer P/B | $16.20 | 3% | median 9.1× · 7 peers |
| Peer P/S | $14.23 | 9% | median 6.4× · 7 peers |
| Market Anchor (SMA50) | $10.21 | 12% | stability 19% (BB-width) |
| Options Expected (B-L 30d) | $13.43 | 16% | 10 strikes · skew +0.48 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $2.8B
- Employees
- 647
- List Date
- 2013-10-17
- CIK
- 0001368514
- Last Earnings
- Nov 4 after close · +26.0% vs ±17.9% expected
- Next Earnings
- ~Feb 24, 2027 (estimated)
- Headquarters
- Ramsey, NJ
- Homepage
- https://www.admabiologics.com
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.21% | -1.36% | -4.65% | 14.07% | -10.13% | -3.24% | -0.02% |
| Feb | -5.71% | 0.00% | -5.84% | 1.13% | -0.49% | -11.03% | -3.66% |
| Mar | -27.27% | 11.59% | -6.76% | 19.57% | 25.33% | -45.66% | -3.87% |
| Apr | 7.10% | -3.16% | 0.90% | -0.31% | 22.55% | 12.51% | 6.60% |
| May | -8.38% | 8.47% | 19.01% | 43.18% | -14.74% | -24.14% | 3.90% |
| Jun | -8.57% | -2.94% | -7.98% | 13.97% | -10.87% | 5.95% | -1.74% |
| Jul | -2.52% | 5.42% | 13.08% | 6.32% | 4.59% | -1.57% | 4.22% |
| Aug | -15.72% | 33.00% | -7.23% | 41.25% | -10.71% | 7.44% | 8.01% |
| Sep | -15.04% | -9.67% | -7.97% | 20.64% | -14.77% | 7.50% | -3.22% |
| Oct | 8.40% | 12.80% | -4.25% | -17.50% | 2.86% | 14.90% | 2.87% |
| Nov | 2.22% | 21.01% | 5.11% | 3.82% | 24.79% | 17.09%* | 12.34% |
| Dec | 5.22% | 20.12% | 18.64% | -12.90% | -5.88% | -- | 5.04% |
| Total | -47.32% | 133.04% | 6.63% | 203.28% | 0.37% | -35.30% | 43.45% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $11.26
SMA 50: $10.28
SMA 200: $10.80
Current: $12.96
EMA 12: $11.76
EMA 26: $11.16
MACD: 0.6032 | Signal: 0.1558
BULLISH
ADX (14): 28.89
TREND
+DI: 32.67
−DI: 13.47
Momentum Oscillators
RSI (14): 67.19
NEUTRAL
Stoch %K: 77.23
Stoch %D: 60.28
Williams %R: -22.87
Volume & Volatility
BB Upper: $12.86
BB Lower: $9.66
OVERBOUGHT
OBV: -115,552,005
Vol SMA 20: 4,030,834
Vol ROC: -6.04%
ATR: $0.67
True Range: $0.58
HV 20: 92.7%
HV 30: 77.3%
HV 60: 62.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before ADMA’s Nov 4 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (6/10)
Key drivers:
- Technical indicators suggest a weak trend, with RSI indicating neutral sentiment
- Recent news headlines are overwhelmingly negative, driving market sentiment
Primary risks:
- High concentration of negative news headlines may lead to further price declines
- Weaker trend strength and RSI signal imply limited upside potential
Investment thesis: ADMA's recent performance is influenced by the company's securities class action lawsuits. As a result, investors should consider the stock's risk profile before making an investment decision.
Recent news sentiment impact: The negative news headlines have contributed to ADMA's recent price decline and may continue to influence market sentiment.
Technical Analysis
Trend direction:
- Short-term (1-4 weeks): Neutral
- Medium-term (1-3 months): Bearish
- Long-term (3-12 months): Bullish (based on SMA 200)
Support/resistance levels:
- Lower Bollinger Band: $9.20
- Middle Bollinger Band: $9.60
- Upper Bollinger Band: $10.00
Momentum signals:
- RSI interpretation: Neutral (54.87)
- MACD signal: Bullish (0.14 / -0.04 / 0.14)
Volume analysis:
- Volume SMA 20: 1818660.15
- On-Balance Volume (OBV): -52540393.18
News & Sentiment Analysis
Recent headlines summary: The majority of recent news headlines are negative, focusing on securities class action lawsuits.
Sentiment assessment: Negative (4/5)
Catalyst identification:
- Upcoming event: August 10 deadline for securities class action lawsuit
- Regulatory change: None identified
Market narrative: The negative news headlines have driven market sentiment and may continue to influence ADMA's price movement.
Risk & Volatility Assessment
Risk assessment: Moderate (4/5)
Beta interpretation: Low risk relative to the broader market (beta = 0.81)
Volatility regime: Moderate volatility - stock generally follows market
Options market signals:
- IV rank: 3.0% (Low)
- Current IV: 73.4%
- Expected move: $1.38 (42 DTE), 7-DTE: $0.95
- Volume flow: 46 calls vs 14 puts
- Open interest: 75 calls vs 174 puts
- Put/call volume ratio: 0.30 (Bullish sentiment)
Downside protection:
- Support levels: Lower Bollinger Band ($9.20), Middle Bollinger Band ($9.60)
- Risk management considerations: Stop-loss levels and position sizing considerations
Market Context & Positioning
Sector performance: ADMA's sector is performing relatively poorly
Institutional activity: Institutional interest signals are mixed, with some institutions showing interest in the stock
Correlation analysis: ADMA's price movement is moderately correlated with the broader market (R-squared = 0.19)
Relative valuation: ADMA's stock is trading within a neutral range
Key Levels & Action Items
Critical price levels:
- Support: Lower Bollinger Band ($9.20), Middle Bollinger Band ($9.60)
- Resistance: Upper Bollinger Band ($10.00)
Breakout/breakdown levels:
- Breakout above upper Bollinger Band ($10.00) could trigger a bullish move
- Breakdown below lower Bollinger Band ($9.20) could lead to further declines
Time-sensitive catalysts:
- August 10 deadline for securities class action lawsuit
Risk management:
- Stop-loss levels: Consider setting stop-losses at or near the Lower Bollinger Band ($9.20)
- Position sizing considerations: Adjust position sizes based on market conditions and risk tolerance
Generated
News
All ADMA news →
ASCENIV demand surged while BIVIGAM faced pressure, and receivables lagged the target range.
Earnings History
27 of 29 under expected move
Avg Expected Move
24.00%
Avg Actual Move
9.40%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-19 | After-Close | 29.02% | 6.25% | 0.22x | Within |
| 2021-03-25 | After-Close | 26.83% | 11.71% | 0.44x | Within |
| 2021-05-12 | After-Close | 26.95% | 2.99% | 0.11x | Within |
| 2021-08-12 | After-Close | 9.93% | 1.32% | 0.13x | Within |
| 2021-10-20 | After-Close | 18.92% | 9.01% | 0.48x | Within |
| 2022-01-19 | After-Close | 10.56% | 0.70% | 0.07x | Within |
| 2022-03-24 | After-Close | 64.00% | 8.67% | 0.14x | Within |
| 2022-05-11 | After-Close | 72.03% | 17.48% | 0.24x | Within |
| 2022-08-10 | After-Close | 28.30% | 5.19% | 0.18x | Within |
| 2022-11-09 | After-Close | 24.29% | 27.53% | 1.13x | Exceeded |
| 2023-01-17 | After-Close | 4.39% | 1.75% | 0.40x | Within |
| 2023-03-23 | After-Close | 27.33% | 6.75% | 0.25x | Within |
| 2023-05-10 | After-Close | 34.45% | 10.92% | 0.32x | Within |
| 2023-08-09 | After-Close | 25.37% | 6.16% | 0.24x | Within |
| 2023-11-08 | After-Close | 37.57% | 5.80% | 0.15x | Within |
| 2024-01-08 | After-Close | 24.95% | 5.41% | 0.22x | Within |
| 2024-02-28 | After-Close | 15.80% | 0.37% | 0.02x | Within |
| 2024-05-09 | After-Close | 28.57% | 27.13% | 0.95x | Within |
| 2024-08-08 | Pre-Market | 18.12% | 6.46% | 0.36x | Within |
| 2024-11-07 | After-Close | 20.79% | 14.71% | 0.71x | Within |
| 2025-01-13 | Pre-Market | 12.66% | 11.15% | 0.88x | Within |
| 2025-03-03 | After-Close | 19.11% | 7.45% | 0.39x | Within |
| 2025-05-07 | After-Close | 14.29% | 10.21% | 0.71x | Within |
| 2025-08-06 | After-Close | 16.72% | 9.65% | 0.58x | Within |
| 2025-11-05 | After-Close | 19.19% | 8.72% | 0.45x | Within |
| 2026-02-25 | After-Close | 12.28% | 3.19% | 0.26x | Within |
| 2026-05-06 | After-Close | 16.87% | 15.97% | 0.95x | Within |
| 2026-08-05 | Pre-Market | 18.80% | 3.93% | 0.21x | Within |
| 2026-11-04 | After-Close | 17.89% | 26.05% | 1.46x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
ADMA Options Activity & IV Rank
ADMA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 46.9%
7-DTE IV: 51.2%
Expected Move: $1.50
7-DTE Move: $0.93
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,700
Put Volume: 529
P/C Volume: 0.311
BULLISH
Call OI: 34,246
Put OI: 8,943
P/C OI: 0.261
Total OI: 43,189
ATM Options Pricing
ATM Call: $0.62
ATM Put: $0.88
Call %: 4.8%
Put %: 6.8%
Chain Summary
Chain Volume: 2,229
Chain OI: 43,189
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 80th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
80%
vs own history
GEX tilt
+0.64
OI-weighted, today
Vanna tilt
+0.10
δ-sensitivity to IV
Charm tilt
-0.34
δ-decay vs time
Charm tilt -0.34: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 23 ATM contracts, 8k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)9.2LowNov 9
IV Rank (30 DTE)4.4LowNov 9
Straddle Price (30 DTE)$1.50Nov 9
Beta Analysis
Risk Metrics
Beta: -0.0370
Alpha: 6.66%
Correlation: -0.0085
R-Squared: 0.0%
Stock Volatility: 59.7%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
Notable investors who own ADMA
8 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Duquesne Family Office Family office Stanley Druckenmiller | $23.3M | #36 of 86 | +80.1% | 13F | |
| Fundsmith Asset manager Terry Smith | $13.8M | #39 of 41 | 0.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $11.5M | #1484 of 6285 | -76.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $9.7M | #1598 of 3716 | -66.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $5.5M | #1411 of 3138 | -48.3% | 13F | |
| Point72 Hedge fund Steve Cohen | $3.5M | #1104 of 1945 | -87.4% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $3.4M | #570 of 997 | -15.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $45K | #3418 of 4729 | +57.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ADMA Institutional Ownership (13F)
Filings for 2026-06-30 · 144 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 239,965,428 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
14 filers$27.28M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Stonepine Capital Management, LLC | $7.95M | 29.14% | 2026-06-30 |
| 2 | Caption Management, LLC | $4.60M | 16.87% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $3.30M | 12.11% | 2026-06-30 |
| 4 | Caligan Partners LP | $2.51M | 9.20% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $2.27M | 8.32% | 2026-06-30 |
| 6 | DIADEMA PARTNERS LP | $1.67M | 6.14% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $1.23M | 4.51% | 2026-09-30 |
| 8 | Citadel Advisors LLC Custodian | $1.06M | 3.87% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $1.01M | 3.69% | 2026-09-30 |
| 10 | Jane Street Group, LLC Custodian | $534.01K | 1.96% | 2026-06-30 |
| 11 | BOOTHBAY FUND MANAGEMENT, LLC | $523.12K | 1.92% | 2026-06-30 |
| 12 | Point72 Asset Management, L.P. | $419.34K | 1.54% | 2026-06-30 |
| 13 | Squarepoint Ops LLC | $173.26K | 0.64% | 2026-06-30 |
| 14 | Persistent Asset Partners Ltd | $26.80K | 0.10% | 2026-06-30 |
8 filers$14.26M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $8.37M | 58.70% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $3.10M | 21.75% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.04M | 7.27% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $471.23K | 3.30% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $448.34K | 3.14% | 2026-09-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $385.86K | 2.71% | 2026-06-30 |
| 7 | Point72 Asset Management, L.P. | $293.79K | 2.06% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $151.45K | 1.06% | 2026-09-30 |
ADMA Insider Trading (Form 4)
Latest: 2026-11-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | Adam S Grossman | President and CEO | Mixed Sell −147,000 · Exer +105,000 |
−42,000 | $9.25 | -$1.20M | EDGAR |
| 2026-07-28 | Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | Tax (F) | −3,177 | $8.37 | -$26.6K | EDGAR |
| 2026-07-17 | Terry Kohler | CFO and Treasurer | Award (A) | +85,130 | — | EDGAR | |
| 2026-05-28 | Jerrold B Grossman | Director | Buy (P) | +6,400 | $7.91 | $50.6K | EDGAR |
| 2026-05-14 | Jerrold B Grossman | Director | Buy (P) | +12,500 | $8.01 | $100.1K | EDGAR |
| 2026-05-12 | Jerrold B Grossman | Director | Buy (P) | +12,500 | $8.01 | $100.1K | EDGAR |
| 2026-04-03 | Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | Tax (F) | −20,362 | $9.11 | -$185.5K | EDGAR |
| 2026-03-17 | Adam S Grossman | President and CEO | Mixed Sell −21,000 · Exer +15,000 |
−6,000 | $11.09 | -$237.4K | EDGAR |
| 2026-03-17 | Lawrence P. Guiheen | Director | Mixed Gift +0 · Exer +30,000 |
+30,000 | $3.66 | $109.8K | EDGAR |
| 2026-03-10 | Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | Mixed Tax −14,294 · Other −91,266 · Exer +10,096 · Sell −10,096 |
−105,560 | $11.89 | -$345.5K | EDGAR |
| 2026-03-10 | Adam S Grossman | President and CEO | Tax (F) | −85,951 | $15.39 | -$1.32M | EDGAR |
| 2026-03-09 | Steve Elms | Director | Buy (P) | +14,000 | $15.53 | $217.4K | EDGAR |
| 2026-03-02 | Adam S Grossman | President and CEO | Tax (F) | −54,858 | $15.18 | -$832.7K | EDGAR |
| 2026-02-23 | Brad L. Tade | CFO and Treasurer | Tax (F) | −6,479 | $16.32 | -$105.7K | EDGAR |
| 2026-02-23 | Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | Tax (F) | −8,161 | $16.32 | -$133.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ADMA Insider Holdings
10 insiders · @ $12.96
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Adam S Grossman | President and CEO | 3,256,203 | $42.22M | -$18.82M | 71 | 2026-11-05 |
| 2 | Steve Elms | Director | 2,136,750 | $27.70M | -$17.76M | 19 | 2026-03-09 |
| 3 | Jerrold B Grossman | Director | 551,665 | $7.15M | -$827.3K | 33 | 2026-05-28 |
| 4 | Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | 443,061 | $5.74M | -$565.9K | 18 | 2026-07-28 |
| 5 | Young Kwon | Director | 263,020 | $3.41M | -$898.1K | 9 | 2026-02-11 |
| 6 | Brad L. Tade | CFO and Treasurer | 232,940 | $3.02M | -$317.2K | 7 | 2026-02-23 |
| 7 | Lawrence P. Guiheen | Director | 186,510 | $2.42M | -$494.5K | 22 | 2026-03-17 |
| 8 | Terry Kohler | CFO and Treasurer | 143,149 | $1.86M | $0 | 1 | 2026-07-17 |
| 9 | Alison Cecily Finger | Director | 45,619 | $591.5K | $0 | 3 | 2026-02-11 |
| 10 | Eduardo Rene Salas | Director | 21,579 | $279.8K | $0 | 3 | 2026-02-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ADMA Board & Officers
As of SEC filings through Nov 5, 2026Directors 7
- Adam S Grossman · since Feb 13, 2012
- Jerrold B Grossman · since Feb 13, 2012
- Steve Elms · since Feb 13, 2012
- Lawrence P. Guiheen · since Jul 17, 2012
- Young Kwon · since Oct 15, 2021
- Alison Cecily Finger · since Sep 28, 2023
- Eduardo Rene Salas · since Dec 30, 2024
Officers 3
- Adam S Grossman · President and CEO · listed since Aug 2024
- Terry Kohler · CFO and Treasurer · since Feb 26, 2026
- Kaitlin M. Kestenberg-Messina · COO and SVP, Compliance · since Apr 1, 2024
Changes in the last 10 years (33)
| Feb 26, 2026 | Terry Kohler became CFO and Treasurer |
| Feb 20, 2026 | The company announced the departure of Brad L. Tade as CFO and Treasurer in an SEC filing |
| Dec 30, 2024 | Eduardo Rene Salas became a director |
| Nov 19, 2024 | The company announced the departure of Bryant Fong from the board in an SEC filing |
| Aug 27, 2024 | Adam S Grossman listed as President and CEO (previously President,CEO, and Interim CFO) in SEC filings |
| Jul 24, 2024 | Brad L. Tade became CFO and Treasurer |
| Apr 2, 2024 | Adam S Grossman listed as President,CEO, and Interim CFO (previously President and CEO) in SEC filings |
| Apr 1, 2024 | Kaitlin M. Kestenberg-Messina became COO and SVP, Compliance |
| Feb 26, 2024 | The company announced the departure of Brian Lenz as EVP, CFO in an SEC filing |
| Sep 28, 2023 | Alison Cecily Finger became a director |
| Oct 15, 2021 | Young Kwon became a director |
| Sep 30, 2021 | Perceptive Life Sciences Master Fund Ltd reported in an SEC filing no longer being a 10% owner |
| Sep 30, 2021 | Perceptive Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Sep 30, 2021 | Joseph Edelman reported in an SEC filing no longer being a 10% owner |
| Jun 18, 2020 | Martha J Demski became a director |
| Jan 25, 2019 | Brian Lenz listed as EVP, CFO (previously VP, CFO) in SEC filings |
| Jun 25, 2018 | Steve Elms no longer listed as a 10% owner in SEC filings |
| Jun 25, 2018 | Dov A Md Goldstein no longer listed as a 10% owner in SEC filings |
| Jan 19, 2018 | Biotest Divestiture Trust became a 10% owner |
| Nov 13, 2017 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Nov 13, 2017 | Perceptive Advisors LLC became a 10% owner |
| Nov 13, 2017 | Joseph Edelman became a 10% owner |
| Nov 13, 2017 | Biotest Pharmaceuticals Corp first listed as a director in an SEC filing |
| Jun 8, 2017 | James Mond listed as EVP, CSO and CMO (previously Cso/cmo) in SEC filings |
| Jun 8, 2017 | Bryant Fong no longer listed as a 10% owner in SEC filings |
| Jun 8, 2017 | Brian Lenz listed as VP, CFO (previously Chief Financial Officer) in SEC filings |
| Jun 6, 2017 | Biotest Pharmaceuticals Corp became a 10% owner |
| Jun 6, 2017 | Biotest AG became a director |
| Jun 6, 2017 | Biotest AG became a 10% owner |
| Jun 6, 2017 | Bernhard Ehmer became a director |
| Feb 16, 2017 | Steve Elms first listed as a 10% owner in an SEC filing |
| Feb 16, 2017 | Dov A Md Goldstein first listed as a 10% owner in an SEC filing |
| Feb 16, 2017 | Bryant Fong first listed as a 10% owner in an SEC filing |
Not reported recently (8)
- Martha J Demski · Last reported as a director in an SEC filing dated Mar 8, 2023
- James Mond · Last reported as EVP, CSO and CMO in an SEC filing dated Mar 1, 2021
- Dov A Md Goldstein · Last reported as a director in an SEC filing dated May 1, 2020
- Eric I Richman · Last reported as a director in an SEC filing dated Mar 3, 2020
- Biotest Divestiture Trust · Last reported as a 10% owner in an SEC filing dated Jun 7, 2019
- Biotest Pharmaceuticals Corp · Last reported as a 10% owner in an SEC filing dated May 16, 2018
- Biotest AG · Last reported as a 10% owner in an SEC filing dated May 16, 2018
- Bernhard Ehmer · Last reported as a director in an SEC filing dated Jun 9, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ADMA Proposed Insider Sales (Form 144)
Latest: 2026-11-05
? Form 144 Guide
Last 30d:
1 filing
· $2.0M notice value
· Last 90d:
1 filing
· $2.0M notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Grossman Adam S. (1, $2.0M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-05 | Grossman Adam S. | Director, Officer | 189,000 | $1.98M | 2026-11-05 | Fidelity Brokerage Services, LLC | 10b5-1 | EDGAR |
| 2026-03-10 | Tade Brad L. | Former Officer | 50,026 | $790.9K | 2026-03-10 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | Officer | 10,096 | $155.4K | 2026-03-09 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2026-02-17 | Grossman Adam S. | Director, Officer | 84,000 | $1.35M | 2026-02-17 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2025-10-24 | Grossman Adam S. | Director and Officer | 63,000 | $960.8K | 2025-10-24 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2025-07-15 | Grossman Adam S | Director and Officer | 63,000 | $1.18M | 2025-07-15 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2025-06-12 | ELMS STEVE | Director | 425,621 | $9.31M | 2025-06-12 | Charles Schwab | — | EDGAR |
| 2025-06-09 | Grossman Jerrold B | Director | 10,000 | $206.1K | 2025-06-09 | Fidelity Brokerage Services, LLC | — | EDGAR |
| 2025-06-04 | Lawrence P Guiheen Rev Tr DTD 09/20/19 | Director | 20,000 | $415.0K | 2025-06-04 | UBS Financial Services Inc | — | EDGAR |
| 2025-05-21 | Guiheen Lawrence P. | Director | 9,000 | $184.0K | 2025-05-21 | Fidelity Brokerage Services, LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
104 ETFs hold ADMA
25 shown · $772.30M total exposure · 0.17% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.17% | $172.5M | $103.8B | 2026-11-06 |
| 2 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 4.09% | $121.4M | $3.0B | 2026-11-06 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.10% | $76.2M | $76.6B | 2026-11-06 |
| 4 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $65.4M | — | 2026-09-30 |
| 5 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.62% | $62.0M | $10.0B | 2026-11-05 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.20% | $27.7M | $13.7B | 2026-11-06 |
| 7 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.17% | $27.4M | $15.7B | 2026-11-05 |
| 8 | IJT iShares S&P Small-Cap 600 Growth ETF | iShares (BlackRock) | 0.35% | $25.8M | $7.3B | 2026-11-06 |
| 9 | VXF Vanguard Extended Market ETF | Vanguard | 0.03% | $25.4M | — | 2026-09-30 |
| 10 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $24.0M | — | 2026-09-30 |
| 11 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.19% | $20.7M | $11.1B | 2026-11-06 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.06% | $20.1M | — | 2026-11-05 |
| 13 | SLYG State Street® SPDR® S&P 600™ Small Cap Growth ETF | SPDR (State Street) | 0.37% | $17.0M | $4.6B | 2026-11-05 |
| 14 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.08% | $13.5M | — | 2026-09-30 |
| 15 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.03% | $13.4M | — | 2026-09-30 |
| 16 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.15% | $11.1M | — | 2026-11-05 |
| 17 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.4M | — | 2026-08-31 |
| 18 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.13% | $8.0M | — | 2026-09-30 |
| 19 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $6.7M | — | 2026-09-30 |
| 20 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.49% | $6.4M | $1.3B | 2026-11-06 |
| 21 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 1.09% | $4.0M | $366.3M | 2026-11-06 |
| 22 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $4.0M | $93.2B | 2026-11-06 |
| 23 | VIOG Vanguard S&P Small-Cap 600 Growth ETF | Vanguard | 0.37% | $3.8M | — | 2026-11-05 |
| 24 | PSCH Invesco S&P SmallCap Health Care ETF | Invesco | 1.61% | $2.9M | — | 2026-11-05 |
| 25 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.09% | $2.7M | $3.2B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
18.50
TTM Diluted EPS
$0.70
TTM Revenue
$512.27M
TTM Net Income
$168.96M
TTM Op. Cash Flow
$136.72M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $124.39M | $37.82M | $0.16 | $29.54M |
| Q1 '26 | 2026-03-31 | $114.49M | $45.33M | $0.19 | $58.25M |
| Q4 '25 | 2025-12-31 | $139.16M | $49.38M | $0.20 | $35.64M |
| Q3 '25 | 2025-09-30 | $134.22M | $36.43M | $0.15 | $13.29M |
| Q2 '25 | 2025-06-30 | $121.98M | $34.22M | $0.14 | $21.14M |
| Q1 '25 | 2025-03-31 | $114.80M | $26.90M | $0.11 | $-19.68M |
| Q4 '24 | 2024-12-31 | $117.55M | $111.90M | $0.46 | $50.22M |
| Q3 '24 | 2024-09-30 | $119.84M | $35.91M | $0.15 | $25.03M |
| Q2 '24 | 2024-06-30 | $107.19M | $32.06M | $0.13 | $45.65M |
| Q1 '24 | 2024-03-31 | $81.88M | $17.81M | $0.08 | $-2.22M |
| Q4 '23 | 2023-12-31 | $73.90M | $-17.64M | $-0.08 | $17.60M |
| Q3 '23 | 2023-09-30 | $67.28M | $2.56M | $0.01 | $11.98M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
18.50
P/B
7.61
P/S
6.07
EV/EBITDA
14.11
EV/Sales
6.18
ROE
41.4%
ROA
24.7%
Div Yield
0.00%
FCF Yield
4.40%
Debt/Equity
0.47
Current Ratio
—
Market Cap
$3.11B
as of 2026-11-09
ADMA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $249.0B | 27.0 | +8.2% | +42.0% | 34 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.5% | 56 |
| REGN Regeneron Pharmaceuticals Inc | $93.6B | 20.5 | +18.6% | +19.6% | 58 |
| GMAB Genmab A/S ADS | $33.0B | — | — | +73.4% | 20 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.5% | 39 |
| NBIX Neurocrine Biosciences Inc | $16.7B | 25.0 | +38.0% | +19.9% | 31 |
| TGTX TG Therapeutics, Inc. | $9.2B | 22.2 | +76.1% | +108.3% | 51 |
| ALKS Alkermes Inc. plc | $7.7B | — | +15.3% | +65.1% | 18 |
| ADMA ADMA Biologics, Inc. | $2.8B | 18.5 | +8.0% | −27.5% | 4 |
| Peer median | $25.0B | 22.2 | +15.3% | +53.3% | 37 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
19.53M
SI % of Float
9.08%
Days to Cover
6.55
Short Vol Ratio
46.7%
Free Float
215.07M
Float %
96.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14